Mavacoxib

Source: Wikipedia, the free encyclopedia.
Mavacoxib
JSmol)
  • C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F
  • InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)
  • Key:TTZNQDOUNXBMJV-UHFFFAOYSA-N

Mavacoxib (trade name Trocoxil) is a

veterinary drug
used to treat pain and inflammation in dogs with degenerative joint disease.
COX-2 inhibitor.[2]

Mavacoxib, along with other COX-2 selective inhibitors, celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[3][4]

References

  1. ^ European Public Assessment Report (EPAR): Trocoxil, European Medicines Agency
  2. PMID 20840390
    .
  3. ^ Langreth R (June 23, 2003). "The Chemical Cobbler". Forbes.
  4. ^ "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mavacoxib&oldid=984394260"